Search | Page 2 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs. de novo myelodysplastic syndromes: A report on behalf of the MDS clinical research consortium

    ... some t-MDS patients have an indolent course. Most MDS prognostic models excluded t-MDS patients during development. The performance of the International Prognostic Scoring System (IPSS), revised IPSS (IPSS-R), MD ...

    Research Article last updated 02/03/2017 - 10:09am.

  2. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.

    ... 2 superiority trial of adult patients with low-risk or International Prognostic Scoring System intermediate-1-risk myelodysplastic syndromes and ...

    Research Article last updated 02/21/2017 - 9:49am.

  3. Recurrent Cytogenetic Abnormalities in Myelodysplastic Syndromes

    ... forms the cornerstone of the most widely adopted prognostic scoring systems in MDS, the international prognostic scoring system (IPSS) and the revised ...

    Research Article last updated 01/26/2017 - 11:01am.

  4. Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes

    ... The Revised International Prognostic Scoring System (IPSS-R) was developed for untreated ...

    Research Article last updated 07/18/2016 - 11:04am.

  5. Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher risk myelodysplastic syndromes

    ... and pracinostat was conducted in patients who had International Prognostic Scoring System intermediate-2-risk or high-risk MDS. The primary ...

    Research Article last updated 02/03/2017 - 11:12am.

  6. Safety and efficacy of azacitidine in elderly patients with intermediate to high-risk myelodysplastic syndromes

    ... In patients classified according to the Revised International Prognostic Scoring System (R-IPSS) with intermediate or higher-risk disease, there is ...

    Research Article last updated 02/01/2017 - 8:17am.

  7. Treatment of low-risk myelodysplastic syndromes

    ... of myelodysplastic syndrome (MDS) patients belong to the International Prognostic Scoring System (IPSS) and IPSS-revised (IPSS-R) lower-risk ...

    Research Article last updated 01/26/2017 - 10:42am.

  8. Integrating Frailty, Comorbidity, and Quality of Life in the Management of Myelodysplastic Syndromes.

    ... intermediate-risk disease as classified by the Revised International Prognostic Scoring System (IPSS-R) or those with higher-risk disease for ...

    Research Article last updated 01/24/2017 - 7:25am.

  9. Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes

    ... The revised International Prognostic Scoring System (IPSS-R) was developed in a cohort of untreated ...

    Research Article last updated 04/23/2014 - 12:10pm.

  10. Impact of the revised International Prognostic Scoring System cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndr

    ... was to determine the impact of the 5-group-revised International Prognostic Scoring System -cytogenetic classification on outcome after ...

    Research Article last updated 03/02/2015 - 2:46pm.